Literature DB >> 17587238

Expression of apoptosis regulators in germinal centers and germinal center-derived B-cell lymphomas: insight into B-cell lymphomagenesis.

Eisaku Kondo1, Tadashi Yoshino.   

Abstract

Germinal centers (GC) are unique sites in peripheral lymphoid tissue where clonal selection of B cells takes place in response to stimulation by various antigens. To select a proper B-cell clone for antibody-mediated immunity, multiple apoptotic signals synchronize in the GC, both in negative and positive selection pathways. At the same time, GC have been known to be a major source of B-cell lymphomas including follicular and Burkitt's, and also some diffuse large B-cell lymphomas. Therefore, uncovering the biological characteristics of GC would greatly contribute to understanding lymphomagenesis, or progression of B-cell lymphomas of GC origin. Herein the authors briefly explain the expression and pathophysiological significance of apoptosis regulators in GC, focusing particularly on Bcl-2, Fas (CD95) and a transcription factor, nuclear factor of activated T cells, which seems to play a critical role in regulating cellular dynamics of GC B cells via B-cell antigen receptor. The expression of these molecules is then compared with that of the neoplastic counterpart B-cell lymphomas in order to consider lymphomagenesis of GC origin. In conclusion, follicular lymphoma closely reflected characteristics of GC among these B-cell lymphomas, although it acquires strong expression of apoptosis-resistant gene, bcl-2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17587238     DOI: 10.1111/j.1440-1827.2007.02115.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  8 in total

1.  Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively.

Authors:  Angélica María Gamboa-Cedeño; Mariángeles Castillo; Wenming Xiao; Thomas A Waldmann; Stella Maris Ranuncolo
Journal:  J Cancer Res Clin Oncol       Date:  2019-04-02       Impact factor: 4.553

2.  FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma.

Authors:  L Sehgal; R Mathur; F K Braun; J F Wise; Z Berkova; S Neelapu; L W Kwak; F Samaniego
Journal:  Leukemia       Date:  2014-04-03       Impact factor: 11.528

Review 3.  Dysregulation of germinal centres in autoimmune disease.

Authors:  Carola G Vinuesa; Iñaki Sanz; Matthew C Cook
Journal:  Nat Rev Immunol       Date:  2009-12       Impact factor: 53.106

4.  Epstein-Barr virus Latent Membrane Protein 2A (LMP2A)-mediated changes in Fas expression and Fas-dependent apoptosis: Role of Lyn/Syk activation.

Authors:  Ryan Incrocci; Samira Hussain; Amanda Stone; Kathryn Bieging; Lauren A C Alt; Michael J Fay; Michelle Swanson-Mungerson
Journal:  Cell Immunol       Date:  2015-08-04       Impact factor: 4.868

5.  Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex.

Authors:  Jillian F Wise; Zuzana Berkova; Rohit Mathur; Haifeng Zhu; Frank K Braun; Rong-Hua Tao; Anita L Sabichi; Xue Ao; Hoyoung Maeng; Felipe Samaniego
Journal:  Blood       Date:  2013-04-18       Impact factor: 22.113

Review 6.  Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma.

Authors:  Etienne Leveille; Nathalie A Johnson
Journal:  Cancers (Basel)       Date:  2021-04-30       Impact factor: 6.639

7.  Hetero-oligomerization between the TNF receptor superfamily members CD40, Fas and TRAILR2 modulate CD40 signalling.

Authors:  Cristian R Smulski; Marion Decossas; Neila Chekkat; Julien Beyrath; Laure Willen; Gilles Guichard; Raquel Lorenzetti; Marta Rizzi; Hermann Eibel; Pascal Schneider; Sylvie Fournel
Journal:  Cell Death Dis       Date:  2017-02-09       Impact factor: 8.469

8.  Quantification of cells expressing markers of proliferation and apoptosis in chronic tonsilitis.

Authors:  V Avramović; V Petrović; M Jović; P Vlahović
Journal:  Acta Otorhinolaryngol Ital       Date:  2015-10       Impact factor: 2.124

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.